D C: PM received, but send not working. My advice is that

New Post Public Reply Private Reply Replies (0) Message Board
bellsandwhistles DivineCorners #12759
D C: PM received, but send not working. My advice is that the professional contact the Dharma Hospice for some information.  See https://www.facebook.com/berkeleybio

I fully understand the frustration. The variation in policies is irrational. However, mmj has reached critical mass, and everthing is changing quickly. It may also interest you to know that important media have gotten wind of Dharmanol.

The following article that critiques a recent university study may be of use in relation to the situation you describe and to Dharmanol™ and T-Hydrocan™.

LONDON – Studies have shown that marijuana not only helps fight the symptoms of treating cancer but also the disease itself.  THC, or tetrahydrocannabinol, often gets the credit for battling cancer cells, but a new study shows that THC isn’t working alone.

The study conducted at St. George’s University of London, led by Dr. Wai Liu, examined six non-hallucinogenic chemicals found in marijuana, called cannabinoids. The study found that each of these chemicals showed anti-cancer properties as effective as THC. Furthermore, when these chemicals are used in combination, they have an even greater impact on cancer cells.

The anti-cancer properties of tetrahydrocannabinol (THC), the primary hallucinogenic component of cannabis, has been recognised for many years, but research into similar cannabis-derived compounds, known as cannabinoids, has been limited. Of six cannabinoids studied, each demonstrated anti-cancer properties as effective as those seen in THC. Importantly, they had an increased effect on cancer cells when combined with each other.

Dr Liu said: “This study is a critical step in unpicking the mysteries of cannabis as a source of medicine. The cannabinoids examined have minimal, if any, hallucinogenic side effects, and their properties as anti-cancer agents are promising. These agents are able to interfere with the development of cancerous cells, stopping them in their tracks and preventing them from growing. In some cases, by using specific dosage patterns, they can destroy cancer cells on their own.”

Opponents of medical marijuana often claim that the drug is unnecessary because of synthetic drugs like Marinol. However , Marinol contains only (synthetic) THC and none of the other cannabinoids proven to fight cancer, so it delivers only a fraction of the benefits that medical marijuana has to offer.
http://www.thedailychronic.net/2013/25922/ant...-revealed/

More info:

D. Gold
"Cannabinoid medicine in larger doses works in several different manners. Malignant cells are killed while adjacent healthy cells are strengthened. Healthy cells are induced to die on schedule (apoptosis), and the rate that cancer spreads (metastasizes) is greatly limited. I really believe that our new Dharmanol™ preparation will enable a cancer patient to take 10 or more times the cannabinoids that are recommended in Simpson therapy, and there may well be no cancer that can stand up to this kind of treatment in an otherwise-healthy individual. Everything we have seen in this field of research indicates that this may well be true." - D. Gold

"On observing the positive results that patients are receiving with standard Simpson therapy, most people studying cannabis medicine agree that if the dose could be increased ten or a hundred times , its already substantial efficacy against cancer will be similarly enhanced. Now this is possible thanks to the removal of the 'high' from the cannabinoids in the production of Dharmanol™." -D. Gold

PR's

LOS ANGELES, CA--(Marketwired - Nov 25, 2013) - SK3 Group, Inc.'s (OTC Pink: SKTO) subsidiary Medical Greens announces its newest product, T-Hydrocan™, a new medicinal cannabis product line. While the focus of SK3's Berkeley Bio's endeavors lies in the development of potential treatments for cancer utilizing non-psychoactive elements of the cannabis/hemp plant, as reflected in the recently-announced Dharmanol™ product line, many patients have found considerable benefit from oral administration of THC, the psychoactive element found in the cannabis / hemp plant, when used to treat a wide variety of medical conditions.

A synthetic version of THC, Marinol™ has been available by prescription for many years, and is prescribed to remediate the pain and nausea from cancer and the side effects of radiation and chemotherapy. Interestingly, Marinol™ is routinely prescribed to cancer patients, and those who also have access to similar natural cannabis products greatly prefer the natural products over the synthetic pharmaceuticals.

T-Hydrocan™ tablets contain the psychoactive element THC, as well as the complete array of cannabinoids that are naturally present in the cannabis / hemp plant. In addition to the cannabinoids, T-Hydrocan™ tablets contain a steam-distilled extract of cannabis / hemp, containing the natural terpenes and terpenoids which work synergistically with the cannabinoids.

Several different versions of T-Hydrocan™ will be offered, adjusting the basic T-Hydrocan™ formula for different applications. T-Hydrocan™ Whole-Plant™ will contain psychoactive, decarboxylated THC, as well as the entire array of related medicinal elements found in the cannabis / hemp plant. T-Hydrocan™ Citrolene™ will contain a healthy dose of the terpene d-Limonene, which attaches to the same receptors as do tranquilizers such as Valium and Xanax, adding a natural relaxing element to the medicine. T-Hydrocan -- CBD™ will add an amount of CBD equal to the THC.

The T-Hydrocan™ line of cannabis-based medicinals will be available through the dispensaries and collectives that have partnered with Medical Greens' wholesale managed collectives.

"We are pleased to add this new product to the arsenal of products available through Medical Greens to fight cancer and we look forward to adding many more," said President Artemus Mayor. "We expect this product to contribute significantly to the growth of the Company as it meets this underserved market."

SKTO's Medical Greens Announces Start of Distribution of Dharmanol™

LOS ANGELES, CA--(Marketwired - Dec 13, 2013) - SK3 Group, Inc's (OTC Pink: SKTO) subsidiary Medical Greens is pleased to announce that the first batch of Dharmanol™ has been manufactured and is ready to be rolled out for California distribution.

Dharmanol™ (pronounced DAR-mah-nol) will be available in two forms: low-dose, non-psychoactive tablets and high-doses directed to cancer.

The low-dose, non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.

At the opposite end of the spectrum is using Dharmanol™ for cancer. Very large doses can be taken daily with no psychoactive effects. On observing the spectacular results that patients are receiving with standard Simpson therapy, most scientists studying cannabis medicine agree that if the dose could be increased ten or a hundred times , its already substantial efficacy will be greatly increased. Now this is possible thanks to the removal of the "high" from the cannabinoids in the production of Dharmanol™.

These tablets contain an array of the most beneficial non-psychoactive cannabinoids. Each tablet will contain 5 mg. of CBD, 5 mg. of mixed cannabinoids in their non-psychoactive form (known as mixed carboxylates) and 5 mg. of a steam-distilled mixture of the natural terpenes and terpenoids found in cannabis and hemp. The terpene element is thought to be responsible for the increased medicinal efficacy of "whole plant" cannabis preparations. The specific recipe is proprietary to Medical Greens.

"These products are game changers for patients," said SKTO President Artemus Mayor. "Now patients can accurately regulate their dosing with medication, without any worry of the psychoactive effects, or high, that is the natural byproduct of existing products on the market. We are fortunate that our team has been among the first to be able to enhance the consumer, and patient, experience in this manner."




SK3 Group Inc. (SKTO) Stock Research Links

SKTO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 1

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 3

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 5

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 6

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 2

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 4

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Click Fraud Trends in EMEA: Insightful Data Report

Updated Category News Views 153

Introduction to Click Fraud in EMEA In the digital age, understanding the landscape of click fraud has become crucial for businesses engaging in online advertising. Recent findings have illuminated the extent of click fraud in the EMEA region, showcasing significant statistics that could impact advertisers and digital marketers alike. This article delves into the insights...

Continue Reading
EPR Properties Updates on Third Quarter 2024 Financial Results

Updated Category News Views 88

EPR Properties Reports Strong Third Quarter Results EPR Properties (NYSE:EPR) has recently released its operating results for the third quarter. The data highlighted a promising performance across various metrics, indicating effective management strategies and a strong investment pipeline. Financial Overview For the third quarter, EPR Properties reported total revenue of...

Continue Reading
Exploring Recent Options Strategies in Impinj: Insights and Trends

Updated Category News Views 191

Understanding the Current Options Trading Landscape for Impinj In recent times, it seems that major investors are adopting a cautious stance towards Impinj (NASDAQ: PI). It is important for those involved in the market to pay attention to this shift. Observations of the public options markets reveal some notable movements that might indicate potential developments around...

Continue Reading
Snap-On's Financial Landscape: Insights and Future Growth Prospects

Updated Category News Views 93

Snap-On Holds Steady Amid Mixed Quarter Results Baird has recently reaffirmed a Neutral rating on Snap-On (NYSE: SNA) while raising the price target to $290, an increase from the previous $275. This change in outlook follows Snap-On's second quarter performance, which revealed a blend of outcomes across different segments. During this quarter, Snap-On encountered...

Continue Reading
Drone Technology Transformation Fuels Growth in Surveying Markets

Updated Category News Views 160

Drone Technology Revolutionizes Industrial Surveying The drone surveying market is rapidly evolving, driven by an increasing demand for aerial intelligence and precise mapping across various sectors including agriculture, construction, mining, and environmental monitoring. These advancements allow businesses to enhance operations and make crucial real-time decisions using...

Continue Reading